ENTERA BIO IS-0000769 (5DT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has a cash flow conversion efficiency ratio of -0.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.46 Million ≈ $-4.05 Million USD) by net assets (€7.27 Million ≈ $8.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 5DT company net worth for the company's overall valuation and market capitalisation.
ENTERA BIO IS-0000769 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ENTERA BIO IS-0000769 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their cash flow conversion efficiency. See 5DT operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Yuma Sun-shading Technology Corp. Ltd.
SHE:300993
|
0.018x |
|
Weihai Huadong Automation Co Ltd
SHE:002248
|
0.037x |
|
Yulon Nissan Motor Co Ltd
TW:2227
|
-0.012x |
|
Zhengzhou Qianweiyangchu Food Co Ltd
SHE:001215
|
0.044x |
|
Jing Jin Electric Technologies Co Ltd
SHG:688280
|
0.340x |
|
Kehua Holdings Co Ltd Class A
SHG:603161
|
0.076x |
|
NUIX Ltd
AU:NXL
|
0.087x |
|
Jiangxi Selon Industrial Co Ltd
SHE:002748
|
-0.009x |
Annual Cash Flow Conversion Efficiency for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ENTERA BIO IS-0000769 from 2021 to 2025. View today's stock price for ENTERA BIO IS-0000769 for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €13.10 Million ≈ $15.32 Million |
€-7.37 Million ≈ $-8.62 Million |
-0.563x | +33.33% |
| 2024-12-31 | €8.08 Million ≈ $9.45 Million |
€-6.82 Million ≈ $-7.97 Million |
-0.844x | -19.89% |
| 2023-12-31 | €10.39 Million ≈ $12.14 Million |
€-7.31 Million ≈ $-8.55 Million |
-0.704x | +33.81% |
| 2022-12-31 | €11.75 Million ≈ $13.74 Million |
€-12.50 Million ≈ $-14.61 Million |
-1.063x | -164.76% |
| 2021-12-31 | €22.57 Million ≈ $26.38 Million |
€-9.06 Million ≈ $-10.60 Million |
-0.402x | -- |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more